				TF	12/ 165
TRANSMITTEAL OF INFORMATION DISCLOSURE STATEMENT NOV 0 7 2005 (Under 37 CFR 1.97(b) or 1.97(c)) Docket No. 112701-036					
	Boza et al.				
Application No. Filing Date Examiner Customer No. Group Art Ur				Group Art Unit	Confirmation No.
09/646,748 December 11, 2000 Abdel A. Mohamed 29157 1653 7778					
			nts		
		·	450		
three mon application	ths of the date of ent ; before the mailing o	ry of the national stage as se f a first Office Action on the r	et forth in 37 CF nerits, or before	R 1.491 in an in the mailing of a	ternational
		37 CFR 1.97(c)			
CFR 1.97(Final Action	b), provided that the on under 37 CFR 1.	Information Disclosure State 113, a Notice of Allowance	ement is filed be under 37 CFR	efore the mailing 1.311, or an A	date of a
☐ the	statement specified in	37 CFR 1.97(e);	•		
	C	OR .			
	fee set forth in 37 CFI	R 1 17(n)			
	The Inform of a nation Action after CFR 1.97(Final Action otherwise of the control of the contro	The Information Disclosure State of a national application; before the mailing of Action after the filing of a request The Information Disclosure State of Information Disclosure State of Information Disclosure State of Information Under 37 CFR 1. otherwise closes prosecution in the statement specified in the Information Disclosure State of Information Under Information Disclosure State of Information Under Information Unde	Address to: Commissioner for Pate P.O. Box 1450 Alexandria, VA 22313-1: 37 CFR 1.97(b) The Information Disclosure Statement submitted herewith is of a national application other than a continued prosecution three months of the date of entry of the national stage as seapplication; before the mailing of a first Office Action on the machine Action after the filing of a request for continued examination of the Information Disclosure Statement submitted herewith is capplication; before the mailing of a first Office Action on the machine and the filing of a request for continued examination of the Information Disclosure Statement submitted herewith is CFR 1.97(b), provided that the Information Disclosure State Final Action under 37 CFR 1.113, a Notice of Allowance otherwise closes prosecution in the application, and is accommissioned the statement specified in 37 CFR 1.97(e);	(Under 37 CFR 1.97(b) or 1.97(c)) Application No. Filing Date Examiner Customer No. 646,748 December 11, 2000 Abdel A. Mohamed 29157 METHOD FOR PROVIDING GLUTAMINE Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 37 CFR 1.97(b) The Information Disclosure Statement submitted herewith is being filed within of a national application other than a continued prosecution application und three months of the date of entry of the national stage as set forth in 37 CF application; before the mailing of a first Office Action on the merits, or before Action after the filing of a request for continued examination under 37 CFR 1. 37 CFR 1.97(c) The Information Disclosure Statement submitted herewith is being filed after CFR 1.97(b), provided that the Information Disclosure Statement is filed be Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR otherwise closes prosecution in the application, and is accompanied by one of the statement specified in 37 CFR 1.97(e);	Cation No. Filing Date Examiner Customer No. Group Art Unit MADE Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 The Information Disclosure Statement submitted herewith is being filed within three months of a national application other than a continued prosecution application under 37 CFR 1.97(b) The Information Disclosure Statement submitted herewith is being filed within three months of a national application other than a continued prosecution application under 37 CFR 1.53 three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an in application; before the mailing of a first Office Action on the merits, or before the mailing of a Action after the filing of a request for continued examination under 37 CFR 1.114. 37 CFR 1.97(c) The Information Disclosure Statement submitted herewith is being filed after the period spec CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an otherwise closes prosecution in the application, and is accompanied by one of:

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT Docket No. (Under 37 CFR 1.97(b) or 1.97(c)) 112701-036 In Re Application: Boza et al. Customer No. **Group Art Unit** Confirmation No. Application No. Filing Date Examiner 09/646,748 December 11, 2000 Abdel A. Mohamed 29157 1653 7778 Title: METHOD FOR PROVIDING GLUTAMINE Payment of Fee (Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p)) A check in the amount of \$180.00 is attached. ☑ The Director is hereby authorized to charge and credit Deposit Account No. 02-1818 as described below. Charge the amount of X Credit any overpayment. Charge any additional fee required. ☐ Payment by credit card. Form PTO-2038 is attached. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. Certificate of Transmission by Facsimile* Certificate of Mailing by First Class Mail I hereby certify that this correspondence is being deposited I certify that this document and authorization to charge deposit with the United States Postal Service with sufficient postage account is being facsimile transmitted to the United States as first class mail in an envelope addressed to Patent and Trademark Office (Fax. No. "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on November 3, 2005 (Date) (Date) Signature Signature of Person Mailing Correspondence Heather Foster Typed or Printed Name of Person Signing Certificate Typed or Printed Name of Person Mailing Certificate *This certificate may only be used if paying by deposit account. Bules Dated: November 3, 2005 Michael Beckett Reg. No. 48,127 Customer No. 29157 CC:



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Boza et al.

Appl. No.:

09/646,748

Conf. No.:

7778

Filed:

December 11, 2000

Title:

METHOD FOR PROVIDING GLUTAMINE

Art Unit:

1653

Examiner:

Abdel A. Mohamed

Docket No.:

112701-036

Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 37 C.F.R. 1.97, and 37 C.F.R. 1.98, Applicants request that a citation and examination of the references cited below, and on the attached PTO-1449 form be made during the course of examination of the above-identified application for United States patent. Pursuant to 37 C.F.R. 1.98, copies of all foreign patent documents and non-patent documents are enclosed.

OTHER DOCUMENTS

- Hauser et al., "Plasma Amino Acid Concentrations in Term-Born Infants Fed a Whey Predominant or When Hydrolysate Formula," Journal of Parenteral and Enteral Nutrition, Vol. 21, pages 27-30, 1997.
- Räihä et al., "Milk Protein Quantity and Quality in Low-Birthweight Infants: I. Metabolic Responses and Effects on Growth," PEDIATRICS, Vol. 57, pages 659-674, May 1976.
- Rassin et al., "Milk Protein Quantity and Quality in Low-Birth-Weight Infants: II. Effects on Selected Aliphatic Amino Acids in Plasma and Urine," PEDIATRICS, Vol. 59, pages 407 422, March 1997.
- Rigo et al., "Metabolic balance studies and plasma amino acid concentrations in preterm infants fed experimental protein hydrolysate preterm formulas," pages 98-104, 1994.
- Rigo et al., "Nutritional evaluation of protein hydrolysate formulas," EUROPEAN JOURNAL OF CLINICAL NUTRITION, pages \$26-\$38, 1995.

11/08/2005 DEMMANU1 00000034 021818 09646748

01 FC:1806

180.00 DA

Applicants look forward to early and favorable consideration of this matter.

Respectfully submitted,

BELL, BOYD & LLOYD LLC

BY

Michael Beckett Reg. No. 48,127 Customer No. 29157

Dated: November 3, 2005



INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

	PTO	Form	1449
--	-----	------	------

Atty Docket No.	Application No.
112701-036	09/646,748
Applicant	
Boza et al.	
Filing Date	Group
December 11, 2000	1653

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Inventor	Class	Subclass	Filing Date If Appropriate
·						

FOREIGN PATENT DOCUMENTS							
Examiner's	Document	Publication				Trans	lation
Initials	Number	Date	Country	Class	Subclass	Yes	No
,			•				
	-						
						 	
						1	
				1			
	1						
							

Examiner's Initials	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	Hauser et al., "Plasma Amino Acid Concentrations in Term-Born Infants Fed a Whey Predominant or When Hydrolysate Formula," Journal of Parenteral and Enteral Nutrition, Vol. 21, pages 27-30, 1997.
	Räihä et al., "Milk Protein Quantity and Quality in Low-Birthweight Infants: I. Metabolic Responses and Effects on Growth," PEDIATRICS, Vol. 57, pages 659-674, May 1976.
	Rassin et al., "Milk Protein Quantity and Quality in Low-Birth-Weight Infants: II. Effects on Selected Aliphatic Amino Acids in Plasma and Urine," PEDIATRICS, Vol. 59, pages 407 422, March 1997.
	Rigo et al., "Metabolic balance studies and plasma amino acid concentrations in preterm infants fed experimental protein hydrolysate preterm formulas," pages 98-104, 1994.
	Rigo et al., "Nutritional evaluation of protein hydrolysate formulas," EUROPEAN JOURNAL OF CLINICAL NUTRITION, pages S26-S38, 1995.

Examiner:	Date Considered:
*Examiner: Initial if citation considered, whether or not Draw line through citation if not in conformance and no	· · · · · · · · · · · · · · · · · · ·
communication to applicant.	